GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4 Therapeutics Inc (NAS:CCCC) » Definitions » Shareholder Yield %

C4 Therapeutics (C4 Therapeutics) Shareholder Yield % : -18.62% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is C4 Therapeutics Shareholder Yield %?

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, C4 Therapeutics's Shareholder Yield % was -18.62%.


C4 Therapeutics Shareholder Yield % Historical Data

The historical data trend for C4 Therapeutics's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4 Therapeutics Shareholder Yield % Chart

C4 Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shareholder Yield %
Get a 7-Day Free Trial - -0.65 -0.31 -20.58 -64.84

C4 Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.55 -19.47 -6.43 -64.84 -21.95

Competitive Comparison of C4 Therapeutics's Shareholder Yield %

For the Biotechnology subindustry, C4 Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4 Therapeutics's Shareholder Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4 Therapeutics's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where C4 Therapeutics's Shareholder Yield % falls into.



C4 Therapeutics Shareholder Yield % Calculation

C4 Therapeutics's Shareholder Yield % for the quarter that ended in Mar. 2024 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0 %+-24.19 %+2.24 %
=-21.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


C4 Therapeutics  (NAS:CCCC) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


C4 Therapeutics Shareholder Yield % Related Terms

Thank you for viewing the detailed overview of C4 Therapeutics's Shareholder Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


C4 Therapeutics (C4 Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
490 Arsenal Way, Suite 120, Watertown, MA, USA, 02472
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
Executives
Mark Mossler officer: Chief Accounting Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Kendra Adams officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Leonard Reyno officer: Chief Medical Officer 607 NORTH LAS PALMAS AVENUE, LOS ANGELES CA 90004
Utpal Koppikar director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO CA 94080
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Laura Bessen director 4747 EXECUTIVE DRIVE, SUITE 1150, SAN DIEGO CA 92121
Andrew Hirsch director, officer: See Remarks C/O BIND THERAPEUTICS, INC., 325 VASSAR ST, CAMBRIDGE MA 02139
Kelly Schick officer: Chief People Officer C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott N Boyle officer: Chief Business Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Malcolm Salter director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Adam Crystal officer: Chief Medical Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Elena Prokupets director C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Jolie Siegel officer: Chief Legal Officer C/O NEON THERAPEUTICS, INC., 40 ERIE ST., SUITE 110, CAMBRIDGE MA 02139
Stewart Fisher officer: Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Lauren White officer: Chief Financial Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472

C4 Therapeutics (C4 Therapeutics) Headlines

From GuruFocus

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

By Stock market mentor Stock market mentor 01-03-2023